Introduction: The understanding of immune checkpoint molecules' co-expression in non-small cell lung carcinoma (NCLC) is important to potentially design combinatorial immunotherapy approaches.
Methods:
We studied 225 formalin-fixed, paraffinembedded tumor tissues from stage I-III NCLCs -142 adenocarcinomas (ADCs) and 83 squamous cell carcinomas (SCCs) -placed in tissue microarrays. Nine immune checkpoint markers were evaluated; four (programmed death ligand 1 [PD-L1], B7-H3, B7-H4, and indoleamine 2,3-dioxygenase 1 [IDO-1]) expressed predominantly in malignant cells (MCs) and five (inducible T cell costimulator, V-set immunoregulatory receptor, T-cell immunoglobulin mucin family member 3, lymphocyte activating 3, and OX40) expressed mostly in stromal tumor-associated inflammatory cells (TAICs). All markers were examined using a quantitative image analysis and correlated with clinicopathologic features, TAICs, and molecular characteristics.
Results: Using above the median value as positive expression in MCs and high density of TAICs expressing those markers, we identified higher expression of immune checkpoints in SCC than ADC. Common simultaneous expression by MCs was PD-L1 þ B7-H3 þ IDO-1 in ADC and PD-L1 þ B7-H3, or B7-H3 þ B7-H4, in SCC. TAICs expressing checkpoint were significantly higher in current smokers than in never smokers. Almost all the immune checkpoint markers showed positive correlation with TAICs expressing inflammatory cell markers. KRAS-mutant ADC specimens showed higher expression of PD-L1 in MCs and of B7-H3, T-cell immunoglobulin mucin family member 3, and IDO-1 in TAICs than wild type. Kaplan-Meier survival curves showed worse prognosis in ADC patients with higher B7-H4 expression by MCs.
Conclusions:
We found frequent immunohistochemical coexpression of immune checkpoints in surgically resected NCLC tumors and correlated with tumor histology, smoking history, tumor size, and the density of inflammatory cells and tumor mutational status.
Introduction
Inhibitory ligands expressed on tumor and inflammatory cells, in particular programmed cell death-ligand 1 (PD-L1; also known as B7-H1 and CD274), B7-H3 (also known as CD276), and B7-H4 (also known as B7-S1, B7x, and VCTN1), which bind to inhibitory receptors on lymphocytes, play critical roles in the downregulation of T cell function. [1] [2] [3] Similar to these ligands, other checkpoint receptors, such as lymphocyte activating 3 (LAG3; also known as CD223), T-cell immunoglobulin mucin family member 3 (TIM3; also known as HAVcr2), and V-set immunoregulatory receptor (VISTA), which are upregulated mainly on tumorinfiltrating T cells, have been associated with inhibition of the immune response. 4 Other immune checkpoints, including certain metabolic enzymes, such as indoleamine 2,3-dioxygenase (IDO), which is expressed by malignant cells (MCs) and infiltrating myeloid cells play an important role in lymphocyte inhibition through the local depletion of amino acids or through specific ligands that can alter lymphocytic functions. [5] [6] [7] In the opposite way, the activation of several costimulatory T cell receptors, including CD137, OX40, CD40, and inducible T cell costimulator (ICOS), is essential to generate an optimal antitumor T cell response. 8, 9 In the last years, blockade or stimulation of many of these individual immune checkpoints, mentioned before, has been shown to be a promising clinical treatment against tumors, but studies of the most reliable and wellvalidated immune checkpoints in the lung tumor microenvironment has not been fully defined. 10, 11 Additional studies of simultaneous co-expression of immune checkpoints can help us to understand the tumor immune evasion and potentially improve our therapeutic approaches to these type of patients in lung cancer.
The aim of this study was to delineate the immunohistochemistry (IHC) expression of a large panel of immune checkpoint markers assessed by quantitative image analysis in non-small cell lung carcinomas (NCLCs) to investigate co-expression patterns and their correlation with the clinicopathologic features and tumor inflammatory cell infiltration and molecular profiles. These findings may help to identify potential novel strategies for lung cancer immunotherapy.
Material and Methods

Tissue Microarray Specimens
Patient NCLC specimens were obtained from the Tissue Biospecimen and Pathology Resource at The University of Texas MD Anderson Cancer Center. Selected tissues from 1997 to 2012 were acquired from patients with primary NCLC, stages I to III, who had not received neoadjuvant therapy and who were evaluated and underwent surgical resection at MD Anderson, following informed consent under protocols approved by the Institutional Review Board.
Tumors were classified using the staging system from the Seventh American Joint Committee on Cancer. 12 Tissue microarray (TMA) sections were prepared at the time of this analysis using three 1.0-mm tissue cores obtained from the center, middle, and periphery of formalin-fixed and paraffinembedded (FFPE) histologic sections. Cases with at least two TMA cores available were included in this analysis. We analyzed a total of 225 tumors, 142 of which were adenocarcinomas (ADCs) and 83 squamous cell carcinomas (SCCs). Clinical and pathologic information, including demographic data, age, sex, tobacco history (yes or no), smoking status (current, former, or never), tumor size, tumor stage, adjuvant treatment and follow-up information for recurrent-free survival (RFS) and overall survival (OS) rates were retrieved from the patients' electronic medical record (Table 1) .
IHC Staining-Based Assessment of Immune Checkpoints
Four-micron-thick sequential TMA sections were used for IHC analysis. The staining was performed using 
Image Analysis-Based Assessment of Immune Checkpoints
To measure the IHC expression of the different markers and quantify their expression, the TMA slides were digitally scanned at Â200 magnification using a ScanScope Aperio AT Turbo slide scanner (Leica Microsystems). The images were visualized using the ImageScope software program (Leica Microsystems), and a pathologist built a TMA block in the Aperio system using the Aperio eSlide Manager (Leica Microsystems) to visualize and analyze each marker on each individual core. Separately, two pathologists (Drs. Parra and Villalobos) performed the image analysis; they were blinded to patients' outcomes. For the analysis, each individual core was divided into tumor cell and tumor stroma compartments using the Aperio tool box (Leica Microsystems). The tumor cell compartment was defined as groups or nests of MCs, and the tumor stroma compartment was represented by the fibrous tissue present between tumor cells. As the immune checkpoints PD-L1, B7-H3, B7-H4, and IDO-1 are expressed mostly in MCs, they were assessed in the tumor cell compartment; by contrast, as ICOS, VISTA, OX40, TIM3, and LAG3 are expressed in tumor-associated immune cells (TAICs), they were examined in the tumor stroma compartment ( Supplementary Fig. 1 ). In the tumor cell compartment, PD-L1, B7-H3, and B7-H4 were examined using an MC membrane algorithm and IDO-1 using a cytoplasmic algorithm, and the expression was quantified as percentage of tumor cells expressing these markers. In the tumor stroma compartment, the expression of PD-L1, B7-H3, B7-H4, IDO-1, ICOS, VISTA, OX40, TIM3, and LAG3 was evaluated in TAICs using the Aperio nuclear algorithm ( Supplementary Fig. 1 ) by counting positive cells, and expression was quantified as density of cells per mm 2 .
Immune Profiling IHC and Whole Exome Sequencing Data
For a subset of tumors examined in this study (118 ADCs and 73 SCCs), immune profiling density data for TAICs using IHC and image analysis assessment had been previously published and were available to correlate the expression of the immune checkpoints with levels of TAICs. 13 The inflammatory cell markers available included CD3 (T cell lymphocytes), CD4 (helper T cell), CD8 (cytotoxic T cell), CD57 (natural killer T cell), granzyme B (cytotoxic lymphocytes), CD45RO (memory T cell), PD-1, forkhead box P3 (regulatory T cell), and CD68 (macrophages).
In addition, a subset of tumors (81 ADCs and 61 SCCs) examined in this study for immune checkpoint expression had whole exome sequencing data available. [14] [15] [16] As published, in the sequencing analysis 28 and 14 genes showed statistically significant mutations in ADC and SCC, respectively. 15, 16 In this study, we correlated the expression of immune checkpoints with the tumor mutation status.
Statistical Methods
In the statistical analysis, values greater than the median percentage in the tumor cells were considered as positive expression of the immune checkpoint markers. Furthermore, using this cutoff for MCs expressing PD-L1, B7-H3, B7-H4, and IDO-1, we were able to identify simultaneous expression of these markers in different sequential slides from the same patient. Additionally, we determined the distribution of lung tumors using four cutoff percentages of MCs expressing PD-L1, B7-H3, B7-H4, and IDO-1 (>1%, >5%, >25%, and >50%, respectively), according to histology. In parallel, TAICs expressing PD-L1, B7-H3, B7-H4, IDO-1, ICOS, VISTA, OX40, TIM3, and LAG3 were divided into high and low densities using the median value; high TAIC densities were those greater than the median, and low TAIC densities were those less than or equal to the median. In the same way, we showed the distribution of TAICs expressing those markers using three levels (tertile) based on regular values of distribution by the statistical software. The chi-square test or Fisher exact test were used to examine differences between groups of patients in the median values of the data in categorical variables, and the Wilcoxon rank-sum test and Kruskal-Wallis test were used to detect differences in continuous variables. Furthermore, supervised cluster analysis was performed to identify relevant groups in ADC and SCC using clinicopathologic characteristics and immune checkpoint marker expression controlling by the continuous variable of the major immune checkpoint, PD-L1, expressed by MCs. The RFS and OS distributions for the patients were estimated using the Kaplan-Meier method. RFS was defined as the interval from surgery to recurrence or last contact, and OS was defined as the interval from surgery to death or last contact. A log-rank test was performed to determine the difference in survival between the groups by individual markers. In addition, we categorized MCs into four groups based on PD-L1, B7-H4, B7H3, and IDO-1 expression (0 ¼ no markers expressed, 1 ¼ one marker expressed, 2 ¼ two markers expressed, 3 ¼ three markers expressed, and 4 ¼ four markers expressed). Regression analysis of the RFS and OS data was performed using the Cox proportional hazards model. The statistical software program R (version 3.3.0; released on May, 2016) was used to perform the computations for all analyses.
Results
Immune Checkpoint Expression
Representative images of immunohistochemical stains for the nine immune checkpoints tested are shown in Figure 1 . Higher positive expression (i.e., above the median) of B7-H3 was observed in MCs of SCCs (median, 26.24%; 49 of 77) when compared with ADCs (median, 9.1%; 60 of 122, p < 0.001) ( Table 2 ), but no other significant differences were detected between these two histologic types. For MCs, PD-L1 þ B7-H3 þ IDO-1 was the most common combination of simultaneously expressed markers, seen in 11% of ADCs (14 of 123) ( Table 3 ). In SCCs, the most common combinations of simultaneously expressed immune checkpoint markers were PD-L1 þ B7-H3 and B7-H3 þ B7-H4, each occurring in 16% of SCCs (9 of 61). Interestingly, no case with PD-L1 þ B7-H3 simultaneous expression in MCs was observed in ADC tumor tissues. B7-H4 was the most common individual marker expressed in ADCs (13%, 16 of 123), and B7-H3 and IDO-1 were the most common individual markers expressed in SCCs (6%, 4 of 61, for each marker). Expression below or equal to the median (i.e., negative expression) of all four immune checkpoint markers in MCs was observed in 14% of ADCs (17 of 123) and in 5% of SCCs (3 of 61) (3). In addition, using the four cutoffs (>1%, >5%, >25%, and >50%), for expression in MCs more frequently used in reports on PD-L1 in the literature, we determined the distribution of lung tumors expressing PD-L1, B7-H3, B7-H4, and IDO-1 according to histologic type (Table 2) . 17 Whereas a higher proportion of SCC specimens were positive for B7-H3, B7-H4, and IDO-1 expression compared with ADC specimens at all cutoff percentages examined, the difference was statistically significant at only >5%, >25%, and >50% for B7-H3 (p ¼ 0.003, p < 0.0001, and p < 0.0001, respectively) and >5% for B7-H4 (p ¼ 0.019). Similarly, using the median value of TAICs expressing PD-L1, B7-H3, B7-H4, IDO-1, ICOS, VISTA, OX40, TIM3, and LAG3, we divided the expression into high and low densities. We found overall higher densities of TAICs expressing those markers in SCCs than in ADCs but without any statistical significance. Furthermore, using three levels of TAIC density (low, intermediate, and high) expressing the immune checkpoint markers, we observed overall lower densities of TAICs expressing those markers in cases of ADC than SCC (Table 2) .
Correlation between Immune Checkpoint Expression and Clinicopathologic Features of NCLC
Supervised clustering allowed the classification of 118 ADCs and 73 SCCs on the basis of their similarities in clinicopathologic features and immune checkpoint marker expression as shown in Figure 2 . The clustering did not show any correlation between the groups controlling by the continuous MC PD-L1 expression and using the clinical categories of sex, stage, tobacco history, and smoking status, but individual correlations of immune checkpoint molecules with clinical and pathologic tumor features were observed in ADC and SCC specimens. Although, most of our cases were smokers, in ADC specimens, MCs with higher PD-L1 expression (median, 44.98%) were observed in current smokers when (14) 3 (5) ADC, adenocarcinoma; SCC, squamous cell carcinoma; PD-L1, programmed death ligand 1; IDO-1, indoleamine 2,3-dioxygenase 1. 
Malignant Cells
Tumor-Associated
Correlation Between Expression of Immune Checkpoints
Combining MCs and TAICs expressing immune checkpoints, we observed more significant correlations in ADC than in SCC (Supplementary Table 2 
Correlation Between Immune Checkpoint Expression and Whole-Exome Sequencing
We sought to analyze associations between mutational phenotypes of NCLC and their immune checkpoint marker profiles as an attempt to enhance our understanding of the interplay between molecular profiles in ADC and SCC and the immune checkpoint pathways. We reviewed the correlation between the immune checkpoints examined in this study and the exonic somatic mutation status of the 28 and 14 significantly mutated genes in ADC and SCC, respectively, available from whole exome sequencing analysis previously published, (Supplementary Table 5) . 16, 18 In ADC, we found that tumors with KRAS mutation had higher levels of MCs expressing PD-L1 and higher densities of TAICs expressing B7-H3, IDO-1, and TIM3 compared with wildtype (WT) tumors. In contrast, as previously published, ADCs with STK11 mutation showed a lower percentage of MCs expressing PD-L1 when compared with WT tumors. 19 Moreover, ZNF479-mutated ADC tumors had a higher percentage of MCs expressing PD-L1 and higher densities of TAICs expressing PD-L1, ICOS, LAG3, and TIM3 than WT tumors. In the same way, ROBO2-mutated ADC tumors showed a higher percentage of MCs expressing PD-L1 and higher densities of TAICs expressing IDO-1 than observed in WT tumors. ADC tumors with an INHBA mutation showed a higher percentage of MCs expressing PD-L1 and higher densities of TAICs expressing LAG3 when compared with WT tumors. TRHDE-mutant ADC also showed a higher percentage of MCs expressing PD-L1 and higher densities of TAICs expressing TIM3 than WT tumors, and tumors with mutant COL12A1 had a higher percentage of MCs expressing B7-H3 when compared with WT tumors. Finally, in ADC, we observed that SETD2-and VCANmutant tumors showed higher densities of TAICs expressing LAG3 and TIM3, respectively, than WT tumors. In SCC, we observed that NFE2L2-mutant tumors had a higher percentage of MCs expressing PD-L1 when compared with WT tumors, and KEAP1-mutant tumors had higher densities of TAICs expressing B7-H3 compared with WT tumors. We observed no other correlations between immune checkpoints expression and whole-exome sequencing features for either histologic type of NCLC.
Correlation Between Immune Checkpoint Expression and NCLC Prognosis
In our study, expression of B7-H4 immune checkpoint marker in NCLC specimens correlated with outcome in univariate and multivariate analysis, (Supplementary Fig. 2 ). For ADC patients, MCs expressing higher B7-H4 (greater than median) were significantly correlated with worse OS (p ¼ 0.003; hazard ratio ¼ 0.409, 95% confidence interval, 0.221-0.757) in both univariate and multivariate analysis after adjustment for smoker status, tumor stage, and adjuvant therapy. Furthermore, patients with higher B7-H4 expression in MCs and lower CD3 (less than median) lymphocyte densities also correlated with worse OS (p ¼ 0.033) in ADC. In univariate analysis for SCC, higher levels (greater than median) of MCs expressing B7-H4 correlated with better outcome (OS, p ¼ 0.040; hazard ratio ¼ 1.868, 95% confidence interval: 1.018-3.429) when compared with patients with lower expression, but it was not significant in the multivariate analysis or when combined those patients with higher or lower CD3 lymphocytes densities. In addition, in univariate analysis grouping the MCs expressing PD-L1, B7-H4, B7H3, and IDO-1 into four groups based on number of markers expressed, we identified a small group of patients (N ¼ 14), those with markers expressed, with a trend to better RFS (p ¼ 0.701) and OS (p ¼ 0.642) when compared with the other groups in NCLC.
Discussion
In this study, we analyzed a TMA set containing tumor specimens obtained from a large cohort of patients with stage I-III NCLC for IHC expression of nine immune checkpoint markers. Using greater than the median value and different cutoffs as positive expression in MCs and high density in TAICs expressing these markers, we identified overall higher expression of immune checkpoints in SCC than ADC. The most common simultaneous expression by MCs was PD-L1 þ B7-H3 þ IDO-1 in ADC and PD-L1 þ B7-H3, or B7-H3 þ B7-H4, in SCC. Overall, TAICs expressing checkpoint markers were significantly higher in current smokers when compared with never smokers and in tumors with larger diameters when compared with smaller sizes. Almost all the immune checkpoint markers showed positive correlation with different TAICs expressing inflammatory cell markers except for CD57 (natural killer cells) in both histologies. Compared with WT tumors, KRAS-mutant ADC specimens showed higher expression of PD-L1 in MCs and of B7-H3, TIM3, and IDO-1 in TAICs. In contrast, STK11-mutant tumors showed lower PD-L1 expression in MCs than WT tumors. Kaplan-Meier survival curves showed worse prognosis in ADC patients with higher B7-H4 expression by MCs when compared with patients with lower expression, and better prognosis in SCC patients with higher B7-H4 expression.
To our knowledge, this is the first paper to describe a large IHC panel of immune checkpoint markers in NCLC patients. Most of these checkpoints have negative regulatory functions over T cell lymphocytes, whereas others, such as OX40 and ICOS provide costimulatory signals for T cell activation in normal and pathologic conditions. [2] [3] [4] 8, 9, 20, 21 However, there is not a defined cutoff value for considering expression of these markers positive or negative. In our study, defining positive expression by using greater than the median value and different cutoffs usually used for PD-L1 expression by MCs, we observed overall higher expression of immune checkpoint markers in SCC when compared with ADC specimens, in particular B7-H3 and B7-H4, suggesting that, similar to PD-L1, these markers are also predominantly expressed in solid tumors. 22 The immune checkpoints are inhibitory pathways hardwired into the immune system that work together for maintaining self-tolerance. It is clear that in NCLC, several immune checkpoint pathways are expressed simultaneously and are correlated as a major mechanism of immune resistance against T cell response. 23, 24 Indeed, we showed that MCs can express more than one checkpoint marker at the same time; in this regard, using sequential staining of our markers, we observed 11 simultaneous or unique expression patterns of PD-L1, B7-H3, B7-H4, and IDO-1 by MCs. Furthermore, we identified that PD-L1 þ B7-H3 þ IDO-1 was the most common combination simultaneously expressed by MCs in ADCs and PD-L1 þ B7-H3, and B7-H3 þ B7-H4 were the most common combinations in SCCs, suggesting that lung tumors can use preferentially more than one pathway to evade the immune system. 25 On the clinical side, the knowledge and understanding of the simultaneous co-expression of targetable immune checkpoint markers by tumors can guide rational combinations of agents that are currently under clinical development to treat this type of patient. In the same way using different cutoffs, overall we observed higher densities of TAICs expressing the immune checkpoint markers in SCC when compared with ADC, suggesting that there are more TAIC antigen experienced or exhausted cells in this type of tumor, possibly reflecting their relations with other factors such as smoking status or chronic obstructive pulmonary disease, that can increase those cell populations. 26 Combining sex, stage, tobacco history, and smoking status in cluster maps from ADC and SCC controlled by PD-L1 as a continuous variable, we were able to visualize a global landscape of these interactions, characterizing the complex scenario that these checkpoint markers have with several factors that can influence their expression. Although the cluster analysis did not show any correlation, individual analysis confirmed that PD-L1 expression is significantly higher in ADC tumors from current smokers than from former or never smokers. 27, 28 In addition, we report for the first time that current smokers have higher densities of TAICs expressing PD-L1, B7-H4, VISTA, and OX40 than do never smokers in ADC. Furthermore, in a comparison by size, large tumors showed a significantly high percentage of MCs expressing B7-H3 in ADC specimens. In addition, large tumors showed a higher percentage of MCs expressing PD-L1 and lower percentage expressing B7-H4 in SCC. In the same way, a higher density of TAICs expressing VISTA was observed in SCC, suggesting that the influence of these individual variables under inflammatory cells reflect the expression and densities of the immune checkpoint markers. Future research with a bigger cohort is needed to characterize each particular component from these immune checkpoint markers.
It is known that most, if not all, malignancies trigger an intrinsic inflammatory response that builds up a protumorigenic microenvironment to create a good tumor response, suggesting that higher expression of these checkpoint markers in MCs and TAICs in NCLC, as we saw in this study, enables tumors to avoid the immune system. 29 We characterized in ADC that MCs expressing PD-L1 have significant positive correlation with MCs expressing B7-H3 and IDO-1 and also with TAICs expressing multiple immune checkpoint markers. Similarly, in SCC MCs expressing PD-L1 had significant positive correlation with MCs expressing IDO-1 and with TAICs expressing almost all of the tested immune checkpoints, suggesting that PD-L1 is the principal marker that may orchestrate the activation of other checkpoint markers in MCs and TAICs to avoid the immune system.
The significance of host immune response in cancer pathogenesis and progression has been further emphasized by the antitumor effects of immune-based therapies. 30 Immune checkpoints are important regulators of the immune system, conducing the initiation of a productive immune response, preventing the onset of autoimmunity, or being used by tumors to avoid the immune system. 31 Our results, in agreement with Spranger et al., 31 argue that these suppressive pathways are essentially driven by the immune system rather than being orchestrated by MCs and TAICs, especially in ADC specimens. We observed the major checkpoint inhibitors such as PD-L1 and also IDO-1 expressed by MCs have a positive correlation with a plethora of inflammatory cells, mostly in ADC, and we found a positive correlation between MCs expressing B7-H3 and CD8 cytotoxic T cell expression in ADC, suggesting that these suppressor markers expressed by MCs can modulate the inflammatory cells, as some other authors have shown in the literature. 32 Because all of the tested immune checkpoint markers were also variably expressed in TAICs, it is not a surprise that these checkpoints had a positive correlation with immune cells, showing the strong relationship between them. 33 The correlations found between immune checkpoint markers and TAICs expressing different intratumoral-infiltrating immune cells suggest that they could be used as predictive biomarkers for response to anti-immune therapy antibodies. 34 Several of these molecules are essential for full T cell activation and functions, such as cytokine productions, to lead an optimal immune response in normal conditions. 4, 35, 36 Interestingly, none of those immune checkpoint markers had significant correlation with TAICs expressing CD57 (natural killer cells) in ADC or SCC, suggesting that natural killer cells may not be controlled by these inhibitory pathways or may be depleted quickly in the tumor microenvironment.
In terms of tumor mutations, we observed significant and frequent associations between common individual mutations in ADC and SCC and our panel of nine immune checkpoint markers. Overall, among all the immune checkpoint markers, KRAS-mutant tumors had high levels of MCs expressing PD-L1, suggesting that PD-L1 is one of the most important immune checkpoint inhibitors related to the KRAS mutation in ADCs. [37] [38] [39] In addition, KRAS-mutant tumors also showed high densities of TAIC expressing B7-H3, IDO-1, and TIM3 compared with WT tumors. In contrast, with another frequent mutation, STK11, as previously published, we observed a lower percentage of MCs expressing PD-L1 when compared with WT tumors, suggesting that this mutation may downregulate the expression of this negative checkpoint marker. 18, 19 In a similar pattern as we observed with KRAS-mutant tumors, we observed with other less frequent mutations in ADC such as ZNF479, roundabout guidance receptor 2 (ROBO2), inhibin beta A subunit (INHBA), thyrotropin releasing hormone degrading enzyme (TRHDE), collagen type XII alpha 1 chain (COL12A1), SET domain containing 2 (SETD2), and versican (VCAN) mutations, which showed upregulation of different checkpoint markers expressed by MCs or TAICs. Similarly, nuclear factor, erythroid 2 like 2 (NFE2L2)-mutant tumors and kelch like ECH associated protein 1 (KEAP1)-mutant tumors showed MCs and TAICs with high expression of PD-L1 in SCC. Our results support the idea that multiple oncogenic signaling mutation pathways, as previously described, such as PD-L1 and others not totally understood, are implicated in cancer pathogenesis. [40] [41] [42] [43] [44] There are no previous data concerning the association between these checkpoint markers' expression and targetable mutation status, suggesting that these associations can be potential predictive markers for response to immune checkpoint inhibitors in mutated tumors. Further, ADCs from smokers have been shown to harbor higher mutation rates compared with those from never smokers, so smoking status could explain the higher expression of immune checkpoints observed in tumors with mutations. Further studies to investigate the underlying mechanisms behind the association of specific driver mutations in NCLC and immune checkpoints are necessary to facilitate the implementation of personalized therapy and to explain the strong predictive marker for response to different immunotherapies. 45 Higher B7-H4 expression in MCs was significantly correlated with poor prognosis in patients with ADC in univariate and multivariate analysis. In addition, worse outcome was detected when we correlated high B7-H4 expression in MCs and low densities of CD3 lymphocytes. There is only one study reported that high B7-H4 expression in NCLC with brain metastases (ADC ¼ 42 and SCC ¼ 2) correlated with poor prognosis. 46 This analysis suggests that B7-H4 expression is an independent factor associated of poor prognosis and is associated with clinicopathologic features in lung adenocarcinoma histology. In addition, our results suggested that densities of CD3 lymphocytes could identify a subgroup of patients with higher B7-H4 MCs expression and low CD3 densities who might benefit with B7-H4 inhibitors that prevent tumor elimination. In univariate analysis, we identified a small group of patients with nonexpression of immune checkpoints by MCs and with a better outcome when compared with the group of patients who expressed combination of immune checkpoint markers, suggesting the poor benefit of combine checkpoint therapies to these patients. In contrast, the group of patients who have a tumor that is expressing more than a single marker provably have more suppressive effects above the immune system reflected in their poor outcome, suggesting that these patients can benefit from using a rational combination of strategies of these immunologic checkpoint targets.
There are a number of limitations for this study. We studied retrospectively collected samples from cases with NCLC and we attempted to examine different available characteristics between immune checkpoint expression and clinicopathologic and mutational status annotations. Most of the patients from our cohort were smokers, which can influence the analysis between nonsmokers and smokers. Although we found correlation between expression of immune checkpoint molecules and KRAS and STK11 mutations, the number of tumors harboring these mutations could be low because of the smoking history of our patients. Our cases were placed in TMA format, which may induce under-or overrepresentation of the marker levels due to tumor heterogeneity.
In summary, our data showed that multiple factors correlated with immune checkpoint expression in NCLC. We could identify different correlations between immune checkpoint markers in surgically resected ADC and SCC specimens and clinicopathologic features. We observed that simultaneous immune checkpoint expression is activated in MCs, and different densities of TAICs expressing immune checkpoints can correlate with smoking habits. We identified several correlations with these checkpoint markers and mutational and outcome status; however, validation of our findings using a similar cohort of patients is needed.
